Literature DB >> 33861190

Co-infection in critically ill patients with COVID-19: an observational cohort study from England.

Vadsala Baskaran1,2,3, Hannah Lawrence3,1,2, Louise E Lansbury2, Karmel Webb2, Shahideh Safavi4,1, Nurul I Zainuddin3, Tausif Huq3, Charlotte Eggleston3, Jayne Ellis5, Clare Thakker5, Bethan Charles6, Sara Boyd7,8, Tom Williams8, Claire Phillips9, Ethan Redmore9, Sarah Platt10, Eve Hamilton10, Andrew Barr10, Lucy Venyo10, Peter Wilson5, Tom Bewick11, Priya Daniel11, Paul Dark12,6, Adam R Jeans6, Jamie McCanny8, Jonathan D Edgeworth8, Martin J Llewelyn9, Matthias L Schmid10, Tricia M McKeever1,2, Martin Beed13,14, Wei Shen Lim1,3.   

Abstract

Introduction. During previous viral pandemics, reported co-infection rates and implicated pathogens have varied. In the 1918 influenza pandemic, a large proportion of severe illness and death was complicated by bacterial co-infection, predominantly Streptococcus pneumoniae and Staphylococcus aureus.Gap statement. A better understanding of the incidence of co-infection in patients with COVID-19 infection and the pathogens involved is necessary for effective antimicrobial stewardship.Aim. To describe the incidence and nature of co-infection in critically ill adults with COVID-19 infection in England.Methodology. A retrospective cohort study of adults with COVID-19 admitted to seven intensive care units (ICUs) in England up to 18 May 2020, was performed. Patients with completed ICU stays were included. The proportion and type of organisms were determined at <48 and >48 h following hospital admission, corresponding to community and hospital-acquired co-infections.Results. Of 254 patients studied (median age 59 years (IQR 49-69); 64.6 % male), 139 clinically significant organisms were identified from 83 (32.7 %) patients. Bacterial co-infections/ co-colonisation were identified within 48 h of admission in 14 (5.5 %) patients; the commonest pathogens were Staphylococcus aureus (four patients) and Streptococcus pneumoniae (two patients). The proportion of pathogens detected increased with duration of ICU stay, consisting largely of Gram-negative bacteria, particularly Klebsiella pneumoniae and Escherichia coli. The co-infection/ co-colonisation rate >48 h after admission was 27/1000 person-days (95 % CI 21.3-34.1). Patients with co-infections/ co-colonisation were more likely to die in ICU (crude OR 1.78,95 % CI 1.03-3.08, P=0.04) compared to those without co-infections/ co-colonisation.Conclusion. We found limited evidence for community-acquired bacterial co-infection in hospitalised adults with COVID-19, but a high rate of Gram-negative infection acquired during ICU stay.

Entities:  

Keywords:  COVID-19; ICU; antibiotic resistance; co-infection

Mesh:

Year:  2021        PMID: 33861190     DOI: 10.1099/jmm.0.001350

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  22 in total

1.  Bacterial Coinfections Increase Mortality of Severely Ill COVID-19 Patients in Saudi Arabia.

Authors:  Abdulaziz Alqahtani; Edrous Alamer; Mushtaq Mir; Ali Alasmari; Mohammed Merae Alshahrani; Mohammed Asiri; Irfan Ahmad; Abdulaziz Alhazmi; Abdullah Algaissi
Journal:  Int J Environ Res Public Health       Date:  2022-02-19       Impact factor: 3.390

Review 2.  COVID-19: Impact on prescribing and antimicrobial resistance.

Authors:  P Ruiz-Garbajosa; R Cantón
Journal:  Rev Esp Quimioter       Date:  2021-09-30       Impact factor: 1.553

3.  Antimicrobial resistance (AMR) in COVID-19 patients: a systematic review and meta-analysis (November 2019-June 2021).

Authors:  Ruwandi M Kariyawasam; Danielle A Julien; Dana C Jelinski; Samantha L Larose; Elissa Rennert-May; John M Conly; Tanis C Dingle; Justin Z Chen; Gregory J Tyrrell; Paul E Ronksley; Herman W Barkema
Journal:  Antimicrob Resist Infect Control       Date:  2022-03-07       Impact factor: 4.887

4.  Detection of bacterial co-infections and prediction of fatal outcomes in COVID-19 patients presenting to the emergency department using a 29 mRNA host response classifier.

Authors:  Nikhil Ram-Mohan; Angela J Rogers; Catherine A Blish; Kari C Nadeau; Elizabeth J Zudock; David Kim; James V Quinn; Lixian Sun; Oliver Liesenfeld; Samuel Yang
Journal:  medRxiv       Date:  2022-03-17

Review 5.  Methicillin-resistant Staphylococcus aureus lung infection in coronavirus disease 2019: how common?

Authors:  Matteo Bassetti; Laura Magnasco; Antonio Vena; Federica Portunato; Daniele Roberto Giacobbe
Journal:  Curr Opin Infect Dis       Date:  2022-04-01       Impact factor: 4.915

6.  High mortality among hospitalized adult patients with COVID-19 pneumonia in Peru: A single centre retrospective cohort study.

Authors:  Guiliana Mas-Ubillus; Pedro J Ortiz; Jorge Huaringa-Marcelo; Paola Sarzo-Miranda; Patricia Muñoz-Aguirre; Alejandra Diaz-Ramos; Kattia Arribasplata-Purizaca; Doris Mendoza; Juan Rojas-Poma; Cristian Marcelo-Ruiz; Pedro Ayala-Diaz; Edwin Hidalgo-Arroyo; Lourdes Tupia-Cespedes
Journal:  PLoS One       Date:  2022-03-08       Impact factor: 3.240

7.  Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

Authors: 
Journal:  Lancet       Date:  2021-05-01       Impact factor: 79.321

8.  Mortality risk and antibiotic use for COVID-19 in hospitalized patients over 80.

Authors:  Andreea Rosca; Thibaut Balcaen; Jean-Philippe Lanoix; Audrey Michaud; Julien Moyet; Ingrid Marcq; Jean-Luc Schmit; Frederic Bloch; Guillaume Deschasse
Journal:  Biomed Pharmacother       Date:  2021-12-28       Impact factor: 6.529

9.  SARS-CoV-2 Spike Protein and Mouse Coronavirus Inhibit Biofilm Formation by Streptococcus pneumoniae and Staphylococcus aureus.

Authors:  Mun Fai Loke; Indresh Yadav; Teck Kwang Lim; Johan R C van der Maarel; Lok-To Sham; Vincent T Chow
Journal:  Int J Mol Sci       Date:  2022-03-18       Impact factor: 5.923

Review 10.  SARS-CoV-2-Legionella Co-Infections: A Systematic Review and Meta-Analysis (2020-2021).

Authors:  Matteo Riccò; Pietro Ferraro; Simona Peruzzi; Alessandro Zaniboni; Silvia Ranzieri
Journal:  Microorganisms       Date:  2022-02-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.